Targeting cytokine and chemokine signaling pathways for cancer therapy
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …
roles in both normal physiology and the pathology of diseases such as cancer. These …
FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions
Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …
development and contributes to tissue and whole-body homeostasis, but can also promote …
Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma
Q Wu, H Ellis, G Siravegna, AG Michel, BL Norden… - Clinical Cancer …, 2024 - AACR
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to
approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible …
approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible …
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …
Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment
Z Wang, F Miao, L Gu, R Zhang, Y Ma, Y Li, J Zheng… - ACS …, 2024 - ACS Publications
Fibrosarcoma, a malignant mesenchymal tumor, is characterized by aggressive
invasiveness and a high recurrence rate, leading to poor prognosis. Anthracycline drugs …
invasiveness and a high recurrence rate, leading to poor prognosis. Anthracycline drugs …
[HTML][HTML] Empowering effective biomarker-driven precision oncology: A call to action
M Lawler, P Keeling, O Kholmanskikh… - European Journal of …, 2024 - Elsevier
Precision oncology has a significant role to play in delivering optimal patient care.
Biomarkers are critical enablers for precision oncology across the continuum of cancer …
Biomarkers are critical enablers for precision oncology across the continuum of cancer …
New clinical trial design in precision medicine: discovery, development and direction
XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …
certain disease are complex and different from each other. Due to the underestimation of the …
Molecular profiling and targeted therapies in gliomas
Y Felistia, PY Wen - Current Neurology and Neuroscience Reports, 2023 - Springer
Abstract Purpose of Review Molecular profiling enables the evaluation of genetic alterations
for the diagnosis and classification of gliomas and the selection of appropriate therapies …
for the diagnosis and classification of gliomas and the selection of appropriate therapies …
FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially …
Background: Diagnostic classification of thyroid malignancy is primarily accomplished
through examination of histomorphological features and may be substantiated and clarified …
through examination of histomorphological features and may be substantiated and clarified …
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
A Lamarca, L Ostios, MG McNamara, C Garzon… - Cancer Treatment …, 2023 - Elsevier
Precision medicine is a major achievement that has impacted on management of patients
diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular …
diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular …